Gastric functional serological biopsy marker - PG
PG I and PG II are two important biomarkers that are widely used in clinical settings to diagnose and monitor various gastrointestinal diseases. PG I, also known as pepsinogen I, is mainly secreted by the gastric chief cells and is an indicator of the overall gastric secretory function. On the other hand, PG II, or pepsinogen II, is secreted by both the chief and pyloric cells and is primarily used to assess the risk of gastric cancer.
Recently, PGR (PG I/PG II ratio) has become a promising tool for clinical applications. The PGR provides valuable information about the gastric mucosal atrophy and the risk of developing gastric cancer. A higher PGR indicates a higher risk of gastric cancer, while a lower PGR suggests a healthier gastric mucosa. Researchers have found that the PGR can be used not only for diagnosing gastric diseases but also for monitoring the effectiveness of treatment. For example, in patients with gastric ulcers, a decrease in PGR after treatment indicates a positive response to therapy. Additionally, in patients with gastric cancer, a higher PGR might serve as a prognostic factor, helping clinicians to determine the best treatment approach.
Diagnostic Kit for Pepsinogen I/Pepsisogen II (Fluorescence immunchromatographic assay), independently developed and produced by Xiamen Wiz Biotech Co., Ltd., is a non-invasive and cost-effective test project and has become a valuable tool in routine clinical practice. It can be easily measured through simple blood tests, eliminating the need for invasive surgeries such as endoscopy. Moreover, the PGR can be used as a screening tool for individuals at higher risk of gastric cancer, allowing for early detection and intervention.
Xiamen Wiz Biotech Co., Ltd. is a high-tech company engages in the research and development, production and sales of rapid diagnostic reagents and instruments. Focusing on technological innovation, WIZBIOTECH develops POCT testing reagents and instruments, and takes advantage of existing channels to expand the medical market, and contributes more in the field of rapid diagnostic POCT.
